SCHEMBL19633720

SCHEMBL19633720

CC(C)c1cc(NC2CCN(S(C)(=O)=O)CC2)ncn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.46
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
CCNE1 P24864 8/20 0.43
CDK2 P24941 8/20 0.43
CCND1 P24385 7/20 0.43
CDK6 Q00534 7/20 0.43
CCNT1 O60563 5/20 0.43
CDK4 P11802 5/20 0.43
CDK9 P50750 5/20 0.43
PRCP P42785 1/20 0.42
TDO2 P48775 1/20 0.41
RORC P51449 1/20 0.41
IKBKB O14920 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
P2RX3 P56373 1/20 0.40
P2RX2 Q9UBL9 1/20 0.40
KCNH2 Q12809 1/20 0.40
IDO1 P14902 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19633480 0.87 PRMT5 (0.40) GPR119CNR1CNR2CCNE1CDK2
SCHEMBL15829421 0.83 GPR119 (0.48) GPR119CNR1CNR2CCNE1CDK2
SCHEMBL18672929 0.82 HRH4 (0.47) CDK2CCND1CDK6CDK4CCND3
SCHEMBL18673000 0.82 PRCP (0.39) GPR119PRCP
SCHEMBL25692885 0.82 MEN1 (0.47) PRCP
SCHEMBL30416551 0.82 MEN1 (0.58) GPR119CNR1CNR2CCNE1CDK2
SCHEMBL29014313 0.82 MEN1 (0.58) GPR119CNR1CNR2CCNE1CDK2
SCHEMBL25715147 0.81 MEN1 (0.40) CCND1CCNT1CDK4CDK9PRCP
SCHEMBL18466045 0.80 GPR119 (0.51) GPR119CNR1CNR2CCNE1CDK2
SCHEMBL28622891 0.80 GPR119 (0.46) GPR119CNR1CNR2CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10980794-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2021-04-20 US disclosed
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 GPR119 843/4885CNR1 3618/4885CNR2 3671/4885
US-10980794-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT6 GPR119 929/4885CNR1 4294/4885CNR2 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.